cvs health glp-1 receptor agonist weight management diabetes treatments Caremark is adding Zepbound, Eli Lilly's obesity drug, back to its commercial insurance plan formularies, more than a year after it stopped covering it in favor of Novo Nordisk's Wegovy. MORE GLP-1 Agonists in Cardiovascular Diseases:
Description
Ramracheya, R

GLP-1 weight-loss drugs are cutting calories and grocery bills, according to a new study from Cornells SC Johnson College of Business using data from Numerator

A., Miners, J
For monitoring of individuals taking GLP-1s, DXA could be considered yearly or every two years, yet such a timeline may impede the identification of early muscle loss and the institution of appropriate interventions